mYXpression is based on a simple principle: each patient is unique and responds differently to prescribed treatments.
With this in mind, the medtech company has developed a test that precisely identifies the biotherapy suited to the biological profile of a patient with rheumatoid arthritis, thus optimizing their therapeutic journey.
Rheumatoid Arthritis: A Disabling Disease
Rheumatoid arthritis is a chronic inflammatory rheumatism (CIR) that affects more than 23 million people worldwide. In France, 0.5% of the population is affected by the disease, which typically manifests at the age of 45 and affects women twice as often as men. The condition results from an immune system malfunction that turns against itself. The origin of the disease is still unknown, but genetic and environmental factors are considered potential causes.
Achieving disease remission is currently the ultimate goal to quickly halt its progression and prevent long-term joint deterioration.
Biotherapies: New Generation Treatments Revolutionizing Rheumatoid Arthritis Care
Biotherapy is a targeted therapy that acts precisely on the mechanisms of inflammation. The advent of these new generation treatments has changed the way patient therapeutic care is approached. Highly effective, biotherapies can alleviate pain and put the disease into remission. But how can one identify, among the ten existing biotherapies, which will be the most efficient for the patient?
To address this challenge, mYXpression has developed a test that provides the doctor and patient with a report called RITI®, indicating the biotherapy that offers the best response quality for the patient. This major advancement ends patients’ therapeutic wandering and offers them a better quality of life.
At the Heart of Tomorrow’s Medicine The mYXpression technology was born from the encounter of its two founders, who, having a mutual friend with rheumatoid arthritis, closely witnessed her suffering despite existing treatments.
Jean-François Robineau, co-founder and scientific and operational director at mYXpression, was convinced that achieving durable disease remission required choosing the right treatment and that a thorough biological analysis, coupled with an innovative mathematical approach, would identify the appropriate treatment for each patient. For a decade, he delved into this idea, leading to the creation of the RITI® test, which combines big data, transcriptomic knowledge, and the high therapeutic level of biotherapies.
This innovative technology revolves around three main competencies:
- Mastery of the latest transcriptomic RNA sequencing technologies (individual multi-genomic signature).
- Massive use of new information technologies and “Big Data” encompassing international clinical studies (digital database).
- Development of massive calculation algorithms and machine learning to generate individualized, efficient, and robust decision support systems that assist the doctor and patient throughout the therapeutic journey.